FindTrial
Sign In

ICL670

DRUG5 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Aplastic AnemiaBeta-ThalassemiaIron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia MajorSickle Cell DiseaseTransfusional Iron Overload

Phase 2

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity
CompletedNCT01044186
Novartis PharmaceuticalsTransfusional Iron Overload
Start: 2003-06-30Updated: 2017-02-23
Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).
CompletedNCT01090323
Novartis PharmaceuticalsSickle Cell Disease
Start: 2004-07-31Updated: 2011-06-06

Phase 3

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
CompletedNCT00061750
Novartis PharmaceuticalsBeta-Thalassemia
Start: 2003-05-31Updated: 2012-04-19

Phase 4

Post Hematopoietic Stem Cell Transplantation
CompletedNCT01610297
Novartis PharmaceuticalsIron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
Start: 2013-09-30End: 2015-10-31Updated: 2016-10-24
Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
TerminatedNCT01818726
Novartis PharmaceuticalsAplastic Anemia
Start: 2014-06-23End: 2016-10-17Updated: 2019-08-16

Related Papers

Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major.
2007-10-19130 citations